Search citation statements

Order By: Relevance
Select...
3
1
3
23
0
2

Year Published

2019
2019
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

3
23
0
2
Order By: Relevance
“…There were four thrombotic TEAEs in this study, two in each group; all were asymptomatic and found as per prespecified, protocol‐defined, or routine imaging. These findings are consistent with a recently published meta‐analysis revealing the prevalence of portal vein thrombosis to be 2.8% in patients with liver disease and thrombocytopenia who were undergoing an elective invasive procedure and treated with TPO receptor agonists . The median maximum PC in patients treated with lusutrombopag was 85.0 × 10 9 /L, with only 1 patient in this study reporting a PC ≥ 200 × 10 9 /L.…”
Section: Discussionsupporting
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…There were four thrombotic TEAEs in this study, two in each group; all were asymptomatic and found as per prespecified, protocol‐defined, or routine imaging. These findings are consistent with a recently published meta‐analysis revealing the prevalence of portal vein thrombosis to be 2.8% in patients with liver disease and thrombocytopenia who were undergoing an elective invasive procedure and treated with TPO receptor agonists . The median maximum PC in patients treated with lusutrombopag was 85.0 × 10 9 /L, with only 1 patient in this study reporting a PC ≥ 200 × 10 9 /L.…”
Section: Discussionsupporting
“…However, a recent meta-analysis of TPO agonists showed that the risk of thrombosis is elevated with eltrombopag only and that avatrombopag and lusutrombopag are associated with minimal risk. 18 However, a larger-scale study and postmarketing surveillance are required to better characterize the risk of thrombotic events more definitively. Third, the invasive procedures performed in the present study were of a minimal to moderately invasive nature and resulted in few bleeding-related events; therefore, the decrease in bleeding-related events with lusutrombopag treatment should be assessed in further studies with patients undergoing more invasive procedures.…”
mentioning
“…A recent meta-analysis from Italy analyzed three of the TPO agonists for risk of PVT-lusutrombopag, avatrombopag, and eltrombopag. 51 In four studies which included 1,953 patients, the risk of PVT was 1.6% in those receiving TPO receptor agonists and 0.6% in the placebo group. There was a trend for an enhanced incidence of PVT in patients treated with TPO receptor agonists compared with placebo, but the difference did not reach significance (OR: 2.8; 95% CI: 0.97-8.16; p ¼ 0.055).…”
Section: Risk Of Portal Vein Thrombosismentioning
“…Importantly, a significant association between PVT and TPO receptor agonists was observed only in patients treated with eltrombopag (OR: 3.8; 95% CI: 1.14-13.2; p ¼ 0.03). 51 A further analysis was performed in this same study to assess the effect of TPO receptor agonists versus placebo on PVT in patients with liver disease and thrombocytopenia, who were undergoing an elective invasive procedure. Three studies, including 514 patients, were analyzed; the follow-up was 1 month.…”
Section: Risk Of Portal Vein Thrombosismentioning
See 1 more Smart Citation